Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 33 Breast Neoplasms 26 Triple Negative Breast Neoplasms 17 Prostatic Neoplasms 16 Fallopian Tube Neoplasms 11 Neoplasms 9 Fanconi Anemia, Complementation Group D1 7 Endometrial Neoplasms 7 Pancreatic Neoplasms 6 Glioma 6 Carcinoma, Ovarian Epithelial 6 Stomach Neoplasms 5 Small Cell Lung Carcinoma 5 Sarcoma 5 Neoplasm Metastasis 5 Cholangiocarcinoma 5 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4 Lymphoma, Non-Hodgkin 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Osteosarcoma 3 Lung Neoplasms 3 Glioblastoma 3 Colorectal Neoplasms 3 Carcinosarcoma 3 Carcinoma, Renal Cell 3 Wilms Tumor 2

Interventions

enzalutamide 4 cabazitaxel 3 Docetaxel 3 Prednisone 2 talazoparib 1 rucaparib 1 pembrolizumab 1 olaparib 1 Zuclomiphene 1 XRP6258 1 Standard of Care 1 Radiosurgery 1 Positron Emission Tomography Computed Tomography 1 LY3023414 1 Injections 1 Carboplatin 1 Abituzumab 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Prostate Cancer Metastatic × olaparib × Clear all

NCT03434158 2022-11-03

IMANOL

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡